Current strategies in whole-brain radiation therapy for brain metastases

Neurosurgery

Volumn 57, Issue 5 SUPPL., 2005, Pages

  Mehta, Minesh P ^a   Khuntia, Deepak ^a  

^a University of Wisconsin Health   (United States)

Author keywords

BCNU (Gliadel ) wafer; Brain tumors; Metastasis; Motexafin gadolinium; Radiation therapy; Radiosensitizer; RSR 13 (efaproxiral); Stereotactic radiosurgery

Indexed keywords

ANTINEOPLASTIC AGENT; BROXURIDINE; EFAPROXIRAL; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; LONIDAMINE; METRONIDAZOLE; MISONIDAZOLE; NIMUSTINE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE;

BONE MARROW SUPPRESSION; BRACHYTHERAPY; BRAIN CANCER; BRAIN METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; GLIOMA; HUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; RADIOSURGERY; REVIEW; STEREOTAXIC SURGERY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 27644508448     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000182742.40978.E7     Document Type: Review

References (91)

1. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259-265, 2001.
2. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22:2101-2107, 2004.
3. Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H, Gonsalves C: Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Bid Phys 42:155-159, 1998.
4. 14C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography. Cancer Chemother Pharmacol 17:121-126, 1986.
5. American College of Surgeons Oncology Group: Studies. Available at: https://www.acosog.org/studies/closed.jsp. Accessed January 9, 2005.
6. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004.
7. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002.
8. Aoyama H, Shirato H, Nakagawa K, Tago M: Interim report of the JROSG99-1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1-4 brain metastases. J Clin Oncol 22, 2004 (abstr).
9. Arbit E, Wronski M, Burt M, Galicich JH: The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer 76:765-773, 1995.
10. Arnold SM, Patchell RA: Diagnosis and management of brain metastases. Hematol Oncol Clin N Am 15:1085-1107, vii, 2001.
11. Bernstein M, Cabantog A, Laperriere N, Leung P, Thomason C: Brachytherapy for recurrent single brain metastasis. Can J Neurol Sci 22:13-16, 1995.
12. Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong CS, Mason W, Buckley C, Levin W, McLean M, Wu JS, Sia M, Kirkbride P: Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38:487-496, 2002.
13. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR: The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9, 1980.
14. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:1633-1638, 1981.
15. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001.
16. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012, 1995.
17. Brem S, Staller A, Wotoczek-Obadia Mea: Interstitial chemotherapy for local control of CNS metastases. Presented at the annual meeting of the Society of Neuro-Oncology, Toronto, ON, Canada, November 18-21, 2004 (abstr).
18. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH: Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: A retrospective study. Cancer 94:2265-2272, 2002.
19. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074-2083, 2001.
20. Chao JH, Phillips R, Nickson JJ: Roentgen-ray therapy of cerebral metastases. Cancer 7:682-689, 1954.
21. Chatani M, Matayoshi Y, Masaki N, Inoue T: Radiation therapy for brain metastases from lung carcinoma: Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 170:155-161, 1994.
22. Chatani M, Teshima T, Hata K, Inoue T: Prognostic factors in patients with brain metastases from lung carcinoma. Strahlenther Onkol 162:157-161, 1986.
23. Chidel MA, Suh JH, Greskovich JF, Kupelian PA, Barnett GH: Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. Radiat Oncol Investig 7:313-319, 1999.
24. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12:249-254, 2001.
25. Coia LR: The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23:229-238, 1992.
26. DeAngelis LM, Currie VE, Kim JH, Krol G, O'Hehir MA, Farag FM, Young CW, Posner JB: The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 7:241-247, 1989.
27. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789-796, 1989.
28. European Organisation for Research and Treatment of Cancer: EORTC 22952/26001: A randomized phase III study of no radiotherapy versus whole brain radiotherapy for 1-3 brain metastases from solid tumour after surgical resection or radiosurgery. Available at: http://groups.eortc.be/radio/Protocols/ 22952_26001.htm. Accessed February 11, 2005.
29. Ewend MG, Brem S, Gilbert M, Goodkin R, Penar P: Treating single brain metastasis with resection, placement of BCNU-polymer wafers, and radiation therapy. Presented at the 72nd Annual Meeting of the American Association of Neurological Surgeons, Toronto, ON, Canada, April 24-26, 2001 (abstr).
30. Eyre HJ, Ohlsen JD, Frank J, LoBuglio AF, McCracken JD, Weatherall TJ, Mansfield CM: Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain: A Southwest Oncology Group study. J Neurooncol 2:325-330, 1984.
31. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
32. Haie-Meder C, Pellae-Cosset B, Laplanche A, Lagrange JL, Tuchais C, Nogues C, Arriagada R: Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26:111-116, 1993.
33. Harwood AR, Simson WJ: Radiation therapy of cerebral metastases: A randomized prospective clinical trial. Int J Radiat Oncol Biol Phys 2:1091-1094, 1977.
34. Hasegawa T, Kondziolka D, Flickinger JC, Germanwala A, Lunsford LD: Brain metastases treated with radiosurgery alone: An alternative to whole brain radiotherapy? Neurosurgery 52:1318-1326, 2003.
35. Hasegawa T, Kondziolka D, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for brain metastases from gastrointestinal tract cancer. Surg Neurol 60:506-514, 2003.
36. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, Roberts JD, Shaw EG, Pearlman AD, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ: A phase 1 study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys 49:1133-1139, 2001.
37. Khuntia D, Mehta M: Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4:981-989, 2004.
38. Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20:53-58, 1991.
39. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999.
40. Kunert MP, Liard JF, Abraham DJ: RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Am J Physiol 271:H602-613, 1996.
41. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:891-895,1981.
42. Lang EF, Slater J: Metastatic brain tumors: Results of surgical and nonsurgical treatment. Surg Clin N Am 44:865-872, 1964.
43. Mahmoud-Ahmed AS, Kupelian PA, Reddy CA, Suh JH: Brain metastases from gynecological cancers: Factors that affect overall survival. Technol Cancer Res Treat 1:305-310, 2002.
44. Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys 54:810-817, 2002.
45. Mañon RR, Oneill A, Mehta M, Knisely J, Wemer-Wasik M, Lazarus H, Wagner HMG: Phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group Study (E6397). J Clin Oncol 22[Suppl], 2004 (abstr).
46. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, Smith W, Dutcher P, Gollob J, Longmate J, Johnson D: Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 128:214-218, 2002.
47. Markesbery WR, Brooks WH, Gupta GD, Young AB: Treatment for patients with cerebral metastases. Arch Neurol 35:754-756, 1978.
48. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21:2529-2536, 2003.
49. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3453, 2002.
50. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004.
51. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, Duncan G, Skingley P, Foster G, Levine M: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470-1476, 1996.
52. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD: Stereotactic radiosurgery for cerebral metastatic melanoma: Factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 42:581-589, 1998.
53. Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD: Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 83:344-353, 1998.
54. Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39:571-574, 1997.
55. Nieder C, Berberich W, Schnabel K: Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 39:25-30, 1997.
56. Order SE, Hellman S, Von Essen CF, Kligerman MM: Improvement in quality of survival following whole-brain irradiation for brain metastasis. Radiology 91:149-153, 1968.
57. Patchell RA: The management of brain metastases. Cancer Treat Rev 29: 533-540, 2003.
58. Patchell RA, Regine WF: The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat 2:111-115, 2003.
59. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998.
60. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990.
61. Patel M, McCully C, Godwin K, Balis FM: Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203-207, 2003.
62. Peirce CB, Bouchard J: Role of radiation therapy in the control of malignant neoplasms of the brain and brain stem. Radiology 55:337-343, 1950.
63. Penitzka S, Steinvorth S, Sehlleier S, Fuss M, Wannenmacher M, Wenz F: Assessment of cognitive function after preventive and therapeutic whole brain irradiation using neuropsychological testing [in German]. Strahlenther Onkol 178:252-258, 2002.
64. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33:339-348, 1995.
65. Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R, Wannenmacher M: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16:3563-3569, 1998.
66. Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB: Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Int J Radiat Oncol Biol Phys 40:57-63, 1998.
67. Prados M, Leibel S, Barnett CM, Gutin P: Interstitial brachytherapy for metastatic brain tumors. Cancer 63:657-660, 1989.
68. Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, Asbell S, Comis R, Curran W, Nelson J, Davis RL, Levin VA, Lamborn K, Phillips TL: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 40:653-659, 1998.
69. Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr: Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-1152, 2004.
70. Reid JM, Stevens DC, Rubin J, Ames MM: Pharmacokinetics of 3-methyl-(triazen-1-yl)irrudazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393-2398, 1997.
71. Richards P, McKissock W: Intracranial metastases. Br Med J 5322:15-18, 1963.
72. Rodrigus P: Motexafin gadolinium: A possible new radiosensitizer. Expert Opin Investig Drugs 12:1205-1210, 2003.
73. Rosenthal DI, Becerra CR, Toto RD, Carbone DP, Frenkel EP: Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am J Clin Oncol 23:593-598, 2000.
74. Shaw E, Scott C, Suh J, Kadish S, Stea B, Hackman J, Pearlman A, Murray K, Gaspar L, Mehta M, Curran W, Gerber M: RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J Clin Oncol 21:2364-2371, 2003.
75. Sheehan J, Niranjan A, Flickinger JC, Kondziolka D, Lunsford LD: The expanding role of neurosurgeons in the management of brain, metastases. Surg Neurol 62:32-40, 2004.
76. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: Long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342-349, 2003.
77. Sneed PK, Lamborn KR, Forstner JM, McDermott MW, Chang S, Park E, Gutin PH, Phillips TL, Wara WM, Larson DA: Radiosurgery for brain metastases: Is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43:549-558, 1999.
78. Sneed PK, Stauffer PR, Gutin PH, Phillips TL, Suen S, Weaver KA, Lamb SA, Ham B, Prados MD, Larson DA: Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors. Neurosurgery 28:206-215, 1991.
79. Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, Regine WF, Weltman E, King VJ, Breneman JC, Sperduto PW, Mehta MP: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53:519-526, 2002.
80. Stea B SJ, Shaw E, Fortin A, Senzer N, Hammoud Y, Craig M, Cagnoni P: Efaproxiral (Efapioxyn) as an adjunct to whole brain radiation therapy for the treatment of brain metastases originating from breast cancer: Updated survival results of the randomized REACH (RT-009) study. Proc San Antonio Breast Cancer Symposium, 2004 (abstr).
81. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2:552-560, 2001.
82. Stupp R, Mason W, Van Den Bent M, Weller M, Fisher B, Taphoorn M, Brandes A, Cairncross G, Lacombe D, Mirimanoff R: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM): Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. J Clin Oncol 22, 2004 (abstr).
83. Stupp R, Newlands E: New approaches for temozolomide therapy: Use in newly diagnosed glioma. Semin Oncol 28:19-23, 2001.
84. Suh J: A phase 3 randomized, open-label comparative study of standard whole brain radiation therapy with supplemental oxygen, with or without concurrent Efaproxyn (efaproxiral), in women with brain metastases from breast cancer, www.allos.com, 2004.
85. 2) with or without Efaproxiral (Efaproxyn) in patients with brain metastases: Updated survival results of the randomized REACH (RT-009) study. Ann Oncol 15[Suppl 3], 2004 (abstr).
86. Suh JH: Efaproxiral: A novel radiation sensitiser. Expert Opin Investig Drugs 13:543-550, 2004.
87. 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: Multicenter safety and feasibility trial. J Neurosurg 99:297-303, 2003.
88. Teicher BA, Wong JS, Takeuchi H, Gravelin LM, Ara G, Buxton D: Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 42:24-30, 1998.
89. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41:44-48, 1997.
90. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR, Brand R, Hermans J: Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583-590, 1993.
91. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5:79-88, 2003.